The Top Line · Fierce Life Sciences

Avoiding 11th hour surprises in clinical trials (Sponsored)

·19 min·1 clip

Unlike the EU's new rules, UK sponsors do not need to resubmit their existing clinical trial applications.

The framing is practical on purpose. Chris Hayden opens a sponsored Top Line conversation with Olive McCormick, Director of Quality at Allmac Clinical Services, whose work covers quality assurance, quality control, and regulatory compliance in the UK and Ireland. McCormick starts with her own remit. She joined Allmac in 1998 and now leads teams overseeing the pharmaceutical quality system, with a close interest in how global regulatory requirements get interpreted. The pressure point is timing. When questions started coming in around regulations and guidance documents, her team asked where sponsors felt exposed and where the rules still left room for judgment. That gave the team something concrete to work with. Sponsor questions became a catalogue of frequently asked questions, standard responses, and a more consistent message. That process also made the hot topics harder to miss. McCormick says the team engaged with the MHA, showed regulators the issues sponsors were raising, and explained how those issues were being handled. The regulator moved fast, by her account, updating a number of guidance documents and giving sponsors clearer footing. Not every answer is the answer a sponsor wants, but even an unwelcome answer can define the next move. Hayden then gets more specific. He asks what has come out of sponsor conversations around the region, and McCormick points to transitional arrangements, product label information, and added requirements around NIMPs. In plain terms, sponsors want to know how to keep ongoing trials unaffected, how to handle clinical label updates, and what they need to do about NIMPs. The close comes back to leadership risk. McCormick says leaders need to understand the risks early because an 11th hour surprise can put the trial, patients, the company, and reputation in a bad place. The practical answer is coordination: get everyone working from the same page before regulatory ambiguity turns into a trial problem.

As heard by us

Clinical trial regulation is treated as an operational problem, and the episode keeps that focus clear.

Clinical trial regulation sits at the center of this episode, with Olive McCormick walking through how teams in the UK and Ireland try to keep up with shifting guidance, transitional arrangements, labeling questions, and the extra demands around NIMPs.

Read the full review in PlayNext →

Why you'd press play

If UK and Ireland trial updates keep turning into tomorrow's problem, start here.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Top Line